UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

Clinical cancer research, 2009-05, Vol.15 (9), p.3094-3102

2009

Volltextzugriff (PDF)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

Journal of medicinal chemistry, 2022-11, Vol.65 (21), p.14614-14629

2022

Volltextzugriff (PDF)

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Cell reports (Cambridge), 2017-09, Vol.20 (12), p.2860-2875

2017

Volltextzugriff (PDF)

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia

The Journal of pharmacology and experimental therapeutics, 2015-03, Vol.352 (3), p.579

2015

Volltextzugriff (PDF)

Activating Transcription Factor 1 and CREB Are Important for Cell Survival during Early Mouse Development

Molecular and Cellular Biology, 2002-03, Vol.22 (6), p.1919-1925

2002

Volltextzugriff (PDF)

DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis

Molecular and Cellular Biology, 2005-03, Vol.25 (5), p.2000-2013

2005

Volltextzugriff (PDF)

Impaired Fetal T Cell Development and Perinatal Lethality in Mice Lacking the cAMP Response Element Binding Protein

Proceedings of the National Academy of Sciences - PNAS, 1998-04, Vol.95 (8), p.4481-4486

1998

Volltextzugriff (PDF)

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Nature (London), 2023-07, Vol.619 (7968), p.160-166

2023

Volltextzugriff (PDF)

Discovery of Novel Spiro[3H‑indole-3,2′-pyrrolidin]-2(1H)‑one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10147-10162

2016

Volltextzugriff (PDF)

Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo

Cancer letters, 2018-05, Vol.421, p.112-120

2018

Volltextzugriff (PDF)

BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models

Neuro-oncology (Charlottesville, Va.), 2023-05, Vol.25 (5), p.913-926

2023

Volltextzugriff (PDF)

Abstract 3084: BI-907828: A novel, potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolonged survival in orthotopic xenograft mouse models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3084-3084

2019

Volltextzugriff (PDF)

The Role of Nuclear Factor-κB Essential Modulator (NEMO) in B Cell Development and Survival

Proceedings of the National Academy of Sciences - PNAS, 2003-02, Vol.100 (3), p.1203-1208

2003

Volltextzugriff (PDF)

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT210-CT210

2021

Volltextzugriff (PDF)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor

Journal of medicinal chemistry, 2022-11, Vol.65 (21), p.14614-14629

2022

Volltextzugriff (PDF)

Abstract 3197: BI-907828, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3197-3197

2019

Volltextzugriff (PDF)

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

Nature (London), 2001-09, Vol.413 (6852), p.179-183

2001

Volltextzugriff (PDF)

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1271-1271

2021

Volltextzugriff (PDF)

Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4865-4865

2018

Volltextzugriff (PDF)

Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4868-4868

2018

Volltextzugriff (PDF)

CREB function is required for normal thymic cellularity and post‐irradiation recovery

European Journal of Immunology, 2004-07, Vol.34 (7), p.1961-1971

2004

Volltextzugriff (PDF)

Abstract 3987: Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3987-3987

2019

Volltextzugriff (PDF)

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

Molecular cancer therapeutics, 2016-10, Vol.15 (10), p.2388-2398

2016

Volltextzugriff (PDF)

Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4866-4866

2018

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(58)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(22)
Animals
(15)
Humans
(15)
Mice
(15)
Cell Line, Tumor
(7)
Oncology
(7)
Cell Biology
(5)
Female
(5)
Mice, Knockout
(5)
Multidisciplinary Sciences
(5)
Pharmacology & Pharmacy
(5)
Science & Technology - Other Topics
(5)
Apoptosis
(4)
Cancer
(4)
Cell Proliferation - Drug Effects
(4)
Chemistry, Medicinal
(4)
Computer Science
(4)
Cyclic Amp Response Element-Binding Protein - Genetics
(4)
Models, Molecular
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia

Activating Transcription Factor 1 and CREB Are Important for Cell Survival during Early Mouse Development

DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis

Impaired Fetal T Cell Development and Perinatal Lethality in Mice Lacking the cAMP Response Element Binding Protein

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Discovery of Novel Spiro[3H‑indole-3,2′-pyrrolidin]-2(1H)‑one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo

BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models

Abstract 3084: BI-907828: A novel, potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolonged survival in orthotopic xenograft mouse models

The Role of Nuclear Factor-κB Essential Modulator (NEMO) in B Cell Development and Survival

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor

Abstract 3197: BI-907828, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic

Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules

CREB function is required for normal thymic cellularity and post‐irradiation recovery

Abstract 3987: Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer

Suchergebnisse filtern